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Cancer is a group of related diseases characterized by an uncontrolled growth of cells beyond their limits 
that can happen in any tissue of the body. Cancer awareness has been increasing because of its high 
incidence, morbidity and mortality, being a key subject in research for new, more effective therapies. 
The immune system is able to fight against tumors with a process known as cancer immunoediting. In this 
aspect, natural killer T (NKT) cells have been proved useful to control tumor growth and are therefore being 
studied for potential new strategies. Two main subsets of NKT cells have been described, type I or iNKT cells 
and type II or vNKT cells, with opposing roles in mediating tumor immunity. The therapeutic studies focus on 
iNKT cell activity because they generally enhance tumor immunity, taking advantage of both direct and 
adjuvant iNKT cell activity. So far the results are preliminary but promising. 
 
Introduction 
•  Describe NKT cells and their general role in the immune system, characterizing the two main 
subtypes of NKT cells as well as the immunoregulatory axis in which they are involved. 
•  Explain the role of NKT cells in tumor immunity, focusing in the mechanisms by which iNKT cells 
seem to mediate cell response against tumors.   
•  Describe the current state of the iNKT cell-based immunotherapy and the main experimental 
procedures used in former studies. 
Aims 
Search in Pubmed database and  in official websites of the World Health Organization and Clinical Trials using 
the following keywords: NKT cells, iNKT cells, tumor, immunotherapy. Original and review papers were 
selected according to their date of publication, quality and specific topic.  
Methodology 
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NKT cells are an heterogeneous subset of lymphocytes that express receptors present both in NK cells 
(NK1.1) and T cells (αβ TCR and CD3). The TCR recognizes glycolipid antigens presented by CD1d, a 
class I-like MHC molecule. 
Two subsets of NKT cells are defined according to heterogeneity of TCR rearrangements: 
 
 
They play an important intermediary role between innate and adaptive immunity, being able to 
respond quickly to stimuli with abundant production of cytokines (mainly TH1 and TH2) that influence 
the polarization of the adaptive response. 
Depending on the specific subset and nature of activation, they have immune enhancing or 
immunosuppressive roles. Type I and type II NKT cells have contrasting roles in most of the cases 
and cross-regulate each other. 
Functions in general immunity 
 
Fig. 1- NKT cell functions. Positive responses for the host are represented in 
green, while deleterious responses are represented in red (1) 
CD40L, CD40 ligand; IFNγ, interferon-γ; IL, interleukin; TCR, T-cell receptor; 
TGFβ, transforming growth factor-β; TNF, tumour-necrosis factor  
Fig. 2- Relationship among type I 
NKT cells, type II NKT cells and 
regulatory T cells (2) 
Fig. 3- IL-13 produced by vNKT cells suppresses cytotoxic T cell tumor immune surveillance through the 
IL-4R-STAT6 pathway to induce TGF-β production by CD11b+Gr-1+ cells (3)  
vNKT cell regulatory pathway  
CD4+ vNKT produce IL-13, which 
together with TNF-α present in the 
microenvironment induces CD11b
+Gr-1+ myeloid cells to secrete TGF-
β, that suppresses specific cytotoxic 
T cells (CD8+) activity against the 
tumor. In some tumors, IL-13 can 
suppress CD8+ T cells stimulating 
M2 macrophages. 
The pathway can be completely 
abrogated by:  
-  removing NKT or myeloid cells 
-  blocking IL-13 or TGF-β 
Ø  Stimulation of iNKT cells: 
-  Direct administration of α-GalCer: it is the strongest activator of iNKT cell activity, 
producing both direct and indirect anti-tumor activities. It inhibits tumor growth and 
increases survival in murine models. However, in clinical trials, no significant clinical 
responses were observed. 
-  Administration of APCs pulsed with α-GalCer: it induces better anti-tumor responses 
from NKT cells than free α-GalCer administration while maintaining safety. Clinical trials 
reported partial responses. 
Ø  Transfer of activated iNKT cells to the patient: 
-  Ex vivo activation of autologous iNKT cells: Isolated iNKT cells or PBMCs (which 
include iNKT cells, among other effector cells) from the patients were expanded  and 
stimulated in vitro and  infused back to patients. The best results  were observed when 
iNKT and α-GalCer-pulsed APCs are infused together. 
-  Adoptive transfer therapy of iPS-derived iNKT cells: Functional iNKT cells are 
generated from induced pluripotent stem cells and infused  to patients. Better results are 
obtained if an activator of TH1 polarization is also infused. This method is especially 
important in patients with low levels of NKT cells.  
Clinical approaches 
Use of iNKT cells in cancer immunotherapy 
−  NKT cells are intermediates between innate and adaptive immunity, mediating immune 
regulatory functions.  
−  NKT cells are divided in iNKT cells and vNKT cells according their TCR rearrangements, and in 
consequence respond to distinct lipid antigens presented by CD1d.  
−  iNKT cells potentiate the antitumor response whereas vNKT cells suppress it.  
−  iNKT cells mediate antitumor response through 3 mechanisms: indirect and direct cytotoxicity 
and modulation of tumor microenvironment. 
−  iNKT cell-based cancer therapy has two main approaches: stimulation of the patient’s iNKT cells 
through injection of exogenous ligands or infusion of iNKT cells activated in vitro.
−  Differences of behavior of the different subsets, the simultaneous unspecific activation of several 
subfamilies of NKT cells, the influence of the microenvironment and the severity of cancer in the 
patients undergoing the studies could partially explain the lack of conclusive results. 
 
Together these results indicate that iNKT cell-based cancer immunotherapy strategies are 
promising. However, more studies to understand the mechanisms of action and the interactions 
with other cell populations are required. 
 
Conclusions and future prospects 
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Functions and characterization of NKT cells 
Fig. 4- Possible mechanisms of iNKT cell-mediated antitumor responses (4) 
Lightning bolt: exertion of direct cytotoxicity; DC: dendritic cell; GAg: glycolipid antigen; TC: tumor cell; TAM: tumor-
associated macrophage; MDSC: myeloid-derived suppressor cell; TME: tumor microenvironment.  
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iNKT cells produce TH1 
cytokines, mainly IFN-γ, 
that contribute to dendritic 
cell maturation and activate 
downstream effector cells 
with cytotoxic activity (NK 
cells and CD8+ T cells) 
iNKT cells produce perforin 
and granzyme and present  
upregulation of CD178 (or 
FasL) or CD253 (TRAIL), 
showing d i rec t d i rec t 
cytotoxicity against tumor 
cells expressing CD1d 
iNKT cells target tumor-
supporting cells, like TAMs 
and MDSCs, and l imit 
angiogenesis, setting an 
i m m u n e - p e r m i s s i v e  
environment that allows 
them to control tumor growth 
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